Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Gan To Kagaku Ryoho ; 50(8): 905-907, 2023 Aug.
Artículo en Japonés | MEDLINE | ID: mdl-37608418

RESUMEN

An 85-year-old woman had been followed up by a local doctor for a cystic lesion of the right breast for 3 years. The lesion was frequently treated with fine needle drainage due to its tendency to slowly increase in size over time. Following the latest drainage of the cystic lesion, the patient became aware of intermittent bleeding from the drainage site, and thus, visited our emergency department. At the time of her hospital visit, the patient had a tense fist-sized mass centered on the C area of the right breast, and the mass was eruptively bleeding from the puncture scar. We performed fine needle drainage and obtained approximately 150 cc of bloody fluid. The bleeding lesion was compressed with a sink and chest band and the patient was hospitalized. When we released the pressure the next day, her right breast was as tense as the initial presentation and purpura were observed. Based on the patient's hematological findings, which showed worsening anemia, we suspected intermittent bleeding from an intracystic tumor. The patient underwent right mastectomy three days after admission. Pathologically, a diagnosis of cholesterol granuloma of the breast was confirmed.


Asunto(s)
Neoplasias de la Mama , Mastectomía , Humanos , Femenino , Anciano de 80 o más Años , Neoplasias de la Mama/cirugía , Mama , Granuloma , Colesterol
2.
Gan To Kagaku Ryoho ; 50(13): 1854-1856, 2023 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-38303230

RESUMEN

In recent years, bridge to surgery(BTS), in which surgery is performed after colorectal stenting for obstructive colorectal cancer, has gradually become popular, and laparoscopic surgery is also a treatment option. From January 2020 to December 2022, we retrospectively evaluated clinicopathological factors in 18 colorectal cancer cases who underwent radical resection after colorectal stenting. We found no difference in patient background, histopathological factors, primary anastomosis rate, stoma creation rate, operative time, postoperative complication rate and length of hospital stay between the laparoscopic surgery(L)and open surgery(O)groups. Blood loss was significantly lower in group L. In T4 patients, laparoscopic surgery after colorectal stenting can be safely performed, but conversion to open surgery may be necessary. Surgery after colorectal stenting should be performed based on preoperative accurate imaging and sufficient experience.


Asunto(s)
Neoplasias Colorrectales , Obstrucción Intestinal , Laparoscopía , Humanos , Neoplasias Colorrectales/cirugía , Neoplasias Colorrectales/complicaciones , Estudios Retrospectivos , Obstrucción Intestinal/etiología , Obstrucción Intestinal/cirugía , Resultado del Tratamiento , Stents/efectos adversos , Laparoscopía/efectos adversos
3.
Gan To Kagaku Ryoho ; 49(13): 1736-1738, 2022 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-36732983

RESUMEN

A 72-year-old man was presented with anemia and diagnosed with sigmoid colon cancer by colonoscopy. CT showed a soft tissue density around the retroperitoneum, leading to the diagnosis of retroperitoneal fibrosis. Stenosis of left ureter, inferior mesenteric artery, and left colic artery due to the soft tissues were detected. Sigmoidectomy and retroperitoneal biopsy were performed, and colorectal anastomosis was completed after confirming the intestinal blood flow by ICG fluorescence angiography. In retroperitoneal fibrosis, identifying blood vessels intraoperatively can be difficult. ICG fluorescence angiography is useful for reliable anastomosis in colorectal cancer surgery with retroperitoneal fibrosis.


Asunto(s)
Laparoscopía , Fibrosis Retroperitoneal , Neoplasias del Colon Sigmoide , Masculino , Humanos , Anciano , Verde de Indocianina , Angiografía con Fluoresceína , Neoplasias del Colon Sigmoide/cirugía , Fuga Anastomótica , Anastomosis Quirúrgica
4.
Medicine (Baltimore) ; 102(1): e32572, 2023 Jan 06.
Artículo en Inglés | MEDLINE | ID: mdl-36607858

RESUMEN

INTRODUCTION: Cowden syndrome is a rare autosomal dominant disease characterized by the development of hamartomas and increased risks of other tumors, including breast, thyroid, and uterine cancers. Most patients with Cowden syndrome show mutations of the phosphatase and tensin homolog (PTEN) gene on chromosome 10; however, some patients with mutations do not show clinical symptoms, while patients with clinical symptoms may not have detectable PTEN mutations. CASE PRESENTATION: A 39-year-old woman with macrocephaly had previously been diagnosed with Cowden syndrome at another hospital, when she presented with the onset of breast cancer. A wide variety of complications were detected, including cerebellar tumors treated by resection, hydrocephalus, and multiple polyps in the stomach and large intestine. She was further diagnosed with adult-onset Lhermitte-Duclos disease as a complication of Cowden syndrome. She subsequently developed a dural arteriovenous fistula treated by transvenous embolization. After transfer to our hospital, she developed adenomatous goiter treated by resection, recurrent breast cancer treated with hormonal therapy, and multifocal oral mucosal papillomatosis. Her older sister had previously been diagnosed with Cowden syndrome and her father was undiagnosed but had macrocephaly, hydrocephalus, and multifocal oral mucosal papillomatosis, suggestive of Cowden syndrome. After consultation with a genetic specialist, analysis of the PTEN gene showed a rare but likely pathogenic germline c.801 + 2T>A variant located at the splice donor site of intron 7. The patient's clinical diagnosis of Cowden syndrome was accordingly confirmed by the genetic findings. Appropriate surveillance procedures were put in place to detect any further tumors. CONCLUSIONS: The clinical symptoms of Cowden syndrome do not always correlate with the genetic results. However, recent improvements in genetic testing suggest the importance of diagnosing this disease using both clinical and genetic approaches, in collaboration with genetic experts, to ensure an accurate diagnosis and appropriate surveillance for malignant tumors.


Asunto(s)
Neoplasias de la Mama , Neoplasias Cerebelosas , Síndrome de Hamartoma Múltiple , Megalencefalia , Papiloma , Humanos , Adulto , Femenino , Síndrome de Hamartoma Múltiple/diagnóstico , Síndrome de Hamartoma Múltiple/genética , Fosfohidrolasa PTEN/genética , Neoplasias Cerebelosas/patología , Neoplasias de la Mama/complicaciones , Megalencefalia/complicaciones , Papiloma/complicaciones , Células Germinativas/patología
5.
Ann Surg Oncol ; 16(9): 2470-8, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19588201

RESUMEN

BACKGROUND: Neoadjuvant chemotherapy (NAC) has been widely accepted for advanced breast cancer patients, and pathological complete remission (pCR) was revealed to be an important prognostic factor. The pCR status of cytologically proven axillary metastases (ALN-pCR) offers a more powerful prognostic predictor than pCR of the main tumor. This study evaluated the clinical significance of residual micrometastases and discusses screening methods after NAC in patients with cytologically proven axillary metastases. METHODS: Eighty patients with a diagnosis of cytologically proven axillary metastases received NAC. All dissected lymph nodes were evaluated using multislice sectioning and cytokeratin immunohistochemistry, and categorized into four groups: no metastases (ALN-pCR), and with metastases 0.2 mm but 2 mm (ALN-mac). Disease-free survival (DFS) and overall survival (OS) were calculated by Kaplan-Meier method based on the status of residual metastases. RESULTS: DFS in patients with ALN-pCR and ALN-itc was significantly longer than that with ALN-mic (P = 0.007, P = 0.045, respectively). OS with ALN-pCR was significantly longer than that with ALN-mic (P = 0.004). There was no significant difference in DFS or OS between ALN-mac and ALN-mic. These data showed the clinical significance of microresidual metastases >0.2 mm after NAC in patients with cytologically proven axillary metastases. CONCLUSIONS: Using multislice sectioning, screening for ALN-mic after NAC was clinically important, and that for ALN-itc was not clinically essential.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Clavícula/patología , Ganglios Linfáticos/patología , Terapia Neoadyuvante , Adulto , Anciano , Axila , Neoplasias de la Mama/secundario , Quimioterapia Adyuvante , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Humanos , Queratinas/metabolismo , Ganglios Linfáticos/cirugía , Metástasis Linfática , Persona de Mediana Edad , Estadificación de Neoplasias , Paclitaxel/administración & dosificación , Pronóstico , Estudios Prospectivos , Tasa de Supervivencia , Resultado del Tratamiento
7.
Breast Cancer ; 20(4): 336-41, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22367960

RESUMEN

BACKGROUND: The systemic management of metastatic breast cancer (MBC) is usually based on ER or HER2 status of the primary tumor. However, the hormonal status or the overexpression of human epidermal growth factor 2 (HER2) may change in every metastatic site because of the effects of the long-term treatment of metastatic cancer with endocrine therapy, chemotherapy, or biological agents. The purpose of this study was to investigate the frequency of change in HER2 expression in primary and distant metastatic tumors in breast cancer patients. Another objective of the study was to examine the effect of the clinical therapy on the basis of HER2 expression in a metastatic tumor. MATERIALS AND METHODS: In our hospital between 1991 to December 2010, retrospectively, 156 patients had biopsy or surgical resection of their metastatic site. All sample were analyzed pathologically to confirm metastatic disease and, second, to evaluate HER2 status by immunohistochemistry or by FISH. RESULTS: The recurrence lesions were resected from the breast or lymph node (n = 67, local lesion), brain (n = 27), lung (n = 16), liver (n = 20), bone (n = 16), and from the stomach, intestine, ovary, and uterus (n = 10). Loss, increase, or no change in HER2 overexpression was observed in 3, 5, and 92%, respectively. Positive changes of HER2 in metastatic sites were 3 (4%) local lesion, 3 (11%) brain, 1 (7%) lung, 0 (0%) liver, 2 (17%) bone, and 0 (0%) others. In 3 of these 8 patients, trastuzumab was administered. In 2 of 3 patients, trastuzumab achieved long stable disease. The negative conversion rate of HER2 expression in metastatic lesions was 37% in patients treated with trastuzumab and 6% in those not treated with trastuzumab, a significant difference between the two groups (P < 0.05). CONCLUSIONS: The results of this study emphasize the significance of confirming HER2 expression in a recurrence lesion. For patients with positive conversion of HER2 status, more treatment options may be available. On the other hand, the rate of loss of HER2 expression was high in patients treated with trastuzumab, suggesting that the results of biopsy may provide an opportunity to reconsider treatment strategies for these patients.


Asunto(s)
Neoplasias de la Mama/patología , Recurrencia Local de Neoplasia/patología , Receptor ErbB-2/metabolismo , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos/uso terapéutico , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Femenino , Estudios de Seguimiento , Humanos , Técnicas para Inmunoenzimas , Hibridación Fluorescente in Situ , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia/tratamiento farmacológico , Recurrencia Local de Neoplasia/metabolismo , Estadificación de Neoplasias , Pronóstico , Receptor ErbB-2/genética , Estudios Retrospectivos , Trastuzumab
8.
Case Rep Oncol ; 5(1): 195-201, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22649339

RESUMEN

With advances in drug treatment of breast cancer, the number of patients experiencing cardiac toxicity or carcinomatous pericarditis is expected to increase. These conditions can cause cardiac tamponade, which is a potentially fatal condition requiring prompt diagnosis and treatment. We experienced 3 breast cancer patients with cardiac tamponade due to carcinomatous pericarditis who survived for prolonged periods after treatment with pericardiocentesis and intrapericardial instillation. The 3 women were 68, 46 and 46 years old, respectively, and receiving treatment for recurrent breast cancer after surgery. They developed dyspnea and cough and were diagnosed with cardiac tamponade by echocardiography. Pericardiocentesis was performed, and cytology of the effusion confirmed the diagnosis of carcinomatous pericarditis. Intrapericardial instillation of cisplatin reduced the cardiac effusion, ameliorating symptoms. The patients died 13, 31 and 14 months later, respectively. In our clinical review of 13 other cases of cardiac tamponade due to breast cancer, 85% achieved local control after the aforementioned local treatments, which were considered to be effective. Although the overall prognosis was poor with a median survival time of only 4 months, some patients were able to survive more than 1 year after local treatment with subsequent systemic therapy.

9.
Breast Cancer ; 14(4): 425-8, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17986810

RESUMEN

Benign epithelial inclusions are uncommonly found in lymph nodes, and ectopic breast tissue in axillary lymph nodes is particularly uncommon. The patient is a 48-year-old woman who had an adenoma of the nipple removed 10 years previously. A swollen lymph node with amorphous calcifications in a clustered distribution on mammogram was found in the left axilla. Fine needle aspiration cytology showed only cystic change. Excisional biopsy was performed and microscopic examination demonstrated that the node contained benign mammary epithelial and glandular inclusions, and no evidence of malignancy. Such cases will be increasingly found due to the widespread use of mammography screening and biopsy of axillary sentinel lymph nodes. Ectopic breast tissue in lymph nodes may be mistaken for malignant lesions. It is most important to identify correctly the epithelial inclusions in lymph nodes to prevent an erroneous diagnosis.


Asunto(s)
Mama , Coristoma/patología , Ganglios Linfáticos/patología , Enfermedades Linfáticas/patología , Biopsia con Aguja Fina , Femenino , Humanos , Persona de Mediana Edad , Biopsia del Ganglio Linfático Centinela
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA